U.S. Pressure Ulcer Treatment Market (2026 - 2033)

U.S. Pressure Ulcer Treatment Market Summary

The U.S. pressure ulcer treatment market size was valued at USD 2.3 billion in 2025 and is projected to grow from USD 2.4 billion in 2026 to USD 3.4 billion by 2033, at a CAGR of 5.4% from 2026 to 2033. The growth of the U.S. pressure ulcer treatment market is driven by the persistent burden of pressure injuries among hospitalized and long-term-care patients, increasing focus on pressure injury prevention and quality outcomes, rising adoption of advanced wound-care technologies, and growing demand for specialized treatment across hospitals, skilled nursing facilities, and home healthcare settings.

The continuing burden of pressure injuries is increasing demand for effective wound-care and treatment solutions across U.S. healthcare settings. For instance, AHRQ Network of Patient Safety Databases Chartbook, 93,807 pressure injury events were reported through December 2024. Among the 17,077 events with valid information on the most advanced stage, 66.6% (11,377 cases) were deep tissue pressure injuries, 10.2% (1,748 cases) were Stage 3, and approximately 21.1% (3,600 cases) were unstageable. 

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The report also found that 77.1% of 17,936 reported events involved patients who had received a preventive intervention, indicating that pressure injuries continue to occur despite preventive measures. Furthermore, 63.8% of reported cases developed a secondary morbidity or had an unknown outcome, while Stage 4 injuries showed the highest reported harm rate at 82%. The substantial number of advanced and potentially harmful pressure injuries supports continued demand for advanced dressings, negative pressure wound therapy, pressure-relieving systems, and other treatment solutions.

To learn more about this report, Download Free Sample Report

Clinical Trials Landscape

Clinical trials are supporting innovation in the U.S. pressure ulcer treatment market by generating clinical evidence on advanced biological therapies for severe and nonhealing wounds. Research is focused on cellular, acellular, and matrix-like products that can accelerate wound closure and improve outcomes in patients with difficult-to-heal Stage III and Stage IV pressure ulcers. For instance, in May 2025, Tiger Biosciences, LLC initiated the Phase 4 NCT06999590 clinical trial in the U.S. to evaluate several cellular, acellular, and matrix-like products (CAMPs), including ACApatch and caregraFT, in combination with standard wound care for nonhealing pressure ulcers. The multicenter, prospective, randomized controlled modified platform trial plans to enroll approximately 500 adult patients with chronic Stage III or Stage IV pressure ulcers. The study will compare weekly applications of these biological products plus standard care with matched standard-of-care controls, with complete wound closure serving as the primary outcome. The trial is expected to be completed in May 2027. The study highlights the growing development of advanced biological and regenerative wound-care therapies and is expected to strengthen clinical evidence supporting the adoption of active & bio-therapies, particularly cellular, acellular, and matrix-based products, in the U.S. pressure ulcer treatment market.

Market Dynamics

The market is experiencing steady growth due to the persistent burden of pressure ulcers among elderly, immobile, hospitalized, and long-term-care patients, along with increasing emphasis on effective wound management and prevention. Pressure ulcer treatment includes advanced wound dressings, negative pressure wound therapy, pressure redistribution and support surfaces, biological skin substitutes, topical agents, and other treatment products that support wound healing and reduce complications. The market is further supported by the growing adoption of standardized wound assessment, hospital-acquired pressure injury prevention protocols, and early intervention practices. In addition, technological advancements such as AI-enabled wound assessment, digital wound monitoring, advanced biomaterials, smart pressure-sensing systems, and portable treatment solutions are improving wound assessment, treatment planning, and patient monitoring across U.S. healthcare settings.

Market Concentration & Characteristics

The U.S. pressure ulcer treatment market has a moderate to high degree of innovation, supported by advances in wound-care products, pressure-relieving technologies, biological skin substitutes, and digital wound assessment. Manufacturers are developing advanced dressings, negative pressure wound therapy systems, smart pressure-monitoring surfaces, antimicrobial products, and AI-enabled wound assessment tools. These technologies aim to improve wound healing, reduce infection risk, support early detection, and provide more accurate monitoring of treatment progress. Innovation is also focused on portable and home-use treatment systems, which can improve access to wound care for patients requiring long-term management.

The U.S. pressure ulcer treatment market has experienced moderate M&A and strategic partnership activity, as companies seek to expand advanced wound-care portfolios, strengthen post-acute care capabilities, and access complementary technologies and distribution channels. For instance, in October 2025, RestorixHealth's acquisition of CūtisCare, which expanded its hospital-based outpatient wound-care and hyperbaric management capabilities and increased its network to nearly 300 hospital, academic medical center, and hospital-system partners across 41 states.

To learn more about this report, Download Free Sample Report

“Integrating CūtisCare and RestorixHealth’s hospital-based services positions us as the leading solution for partners of all sizes across all communities with our expertise spanning from rural hospitals to healthcare systems and teaching hospitals,” said RestorixHealth Chief Executive Officer Ben Dunford. “We are excited to grow with each of our centers and hospital partners and further expand our reach to get more patients the care they need for their hard-to-heal wounds.”

Regulations have a significant impact on the U.S. pressure ulcer treatment market because wound-care products and medical devices must comply with FDA requirements before commercialization, depending on their classification and intended use. FDA regulates applicable wound-care devices, drugs, and biological products, with requirements varying according to product type and risk profile. For instance, FDA classifies certain NPWT devices as Class II medical devices and requires applicable manufacturers to meet premarket notification and other regulatory requirements.

The U.S. pressure ulcer treatment market faces moderate competition from substitute treatment approaches, particularly preventive and conventional wound-management practices. Basic dressings, gauze, repositioning, nutritional support, moisture management, pressure-redistribution mattresses, cushions, and other preventive measures may reduce the need for advanced treatment products, particularly for early-stage pressure injuries. Standardized prevention protocols can also reduce progression to more severe ulcers requiring NPWT, biological therapies, or advanced dressings.

Demand for pressure ulcer treatment products in the U.S. is concentrated across acute care hospitals, long-term acute care hospitals, skilled nursing facilities, long-term care settings, rehabilitation facilities, wound-care clinics, physician offices, and home healthcare. Hospitals are an important end-use setting because pressure injuries are closely associated with immobility, prolonged hospitalization, and complex patient conditions. The importance of hospital-based prevention is reinforced by Centers for Medicare and Medicaid Services’ (CMS's) HAC (Hospital-Acquired Condition) Reduction Program, which links hospital performance on hospital-acquired conditions with Medicare reimbursement.

Analyst Perspective

The market is expected to witness steady growth, driven by the persistent burden of pressure injuries among older, immobile, and medically complex patients, increasing focus on hospital-acquired pressure injury prevention, and rising demand for advanced wound-care solutions. The market is further supported by advancements in advanced dressings, negative pressure wound therapy, pressure-redistribution systems, digital wound assessment, and AI-enabled risk prediction. From an analyst's perspective, companies that focus on developing clinically effective products, improving wound-healing outcomes, supporting home-based care, and demonstrating cost effectiveness will be better positioned to strengthen their competitive advantage. Future market leadership is expected to depend on continuous innovation, expansion into long-term care and home healthcare settings, integration of digital technologies, strong healthcare-provider partnerships, and the ability to deliver cost-effective, outcome-focused pressure ulcer management solutions across the U.S. healthcare system.

Product Insights

The wound care dressings segment dominated the U.S. pressure ulcer treatment market, accounting for 37.6% of the market in 2025. This dominance is supported by the widespread use of advanced dressings for exudate management, moisture balance, wound protection, infection control, and support for tissue healing across different pressure ulcer stages. The segment is also benefiting from continuous product innovation aimed at improving absorption capacity, wear time, patient comfort, and ease of use for healthcare providers. For instance, in September 2024, Solventum launched the V.A.C. Peel and Place Dressing, an all-in-one extended-wear dressing for V.A.C. Therapy. The dressing simplified negative pressure wound therapy application, reduced dressing-change frequency, and supported treatment across various wound types, including pressure ulcers.

"Being able to quickly and safely apply the dressing to deeper and more varied types of wounds, and for it to stay in place for a longer period of time means a reduction in dressing changes, home care visits, and trips to the clinic," said Dot Weir, RN, CWON, CWS, a practicing wound and ostomy care nurse with over four decades of experience. "Because wound care often extends beyond a hospital stay, making the treatment less burdensome and less painful allows patients to get back to their lives more quickly and enables clinicians to ensure consistency of care throughout the healing journey."

The active & bio-therapies segment in the pressure ulcer treatment market is expected to grow at the fastest rate during the forecast period due to increasing interest in advanced therapies for complex, non-healing, and severe pressure ulcers. The segment includes active biomaterials, bioengineered skin substitutes, and growth factors designed to support tissue regeneration, wound closure, and healing. The U.S. regulatory environment also supports continued development of advanced wound-healing technologies, with the FDA overseeing biological and cellular therapies and providing guidance for products intended to treat chronic cutaneous ulcers. Growing clinical interest in regenerative wound care, combined with the limitations of conventional treatment for difficult-to-heal wounds, is supporting greater adoption of these advanced therapies.

Clinical Severity Insights

The stage II segment dominated the pressure ulcer treatment market, accounting for 32.4% of the market in 2025. This dominance is supported by the need for timely diagnosis and treatment to prevent pressure injuries from progressing to deeper tissue damage. Stage II pressure ulcers involve partial-thickness skin loss and commonly require wound protection, moisture management, pressure redistribution, repositioning, and appropriate wound dressings. The U.S. pressure injury burden also remains significant across hospital settings. In the U.S., the 2025 AHRQ Patient Safety Indicator data recorded 34,304 pressure-ulcer cases across 45.7 million hospital discharges, corresponding to an observed rate of 0.75 per 1,000 discharges. The rate was higher among males at 0.92 per 1,000 discharges and among patients aged 65-74 years at 0.88 per 1,000 discharges.

Pressure Ulcer Rate Benchmark Data in the U.S., 2025

Source: The Agency for Healthcare Research and Quality (AHRQ), 2025

To learn more about this report, Download Free Sample Report

The stage IV segment in the pressure ulcer treatment market is expected to grow at the fastest rate during the forecast period driven by the increasing need for advanced and intensive treatment of severe pressure injuries involving extensive tissue damage. Stage IV ulcers may expose muscle, tendon, cartilage, or bone and often require complex wound management, infection control, debridement, surgical intervention, and prolonged clinical care. Growing adoption of negative pressure wound therapy, advanced wound dressings, bioengineered skin substitutes, active biomaterials, and other advanced therapies is supporting treatment demand for severe pressure injuries in U.S. hospitals, long-term care facilities, rehabilitation centers, and specialized wound-care settings.

End Use Insights

The acute care hospital segment dominated the pressure ulcer treatment market, accounting for 41.2% in 2025. This dominance is supported by the large and expanding U.S. hospital infrastructure, high patient volumes, and the concentration of medically complex and mobility-limited patients requiring continuous monitoring and wound management. According to the American Hospital Association, the U.S. had 6,100 hospitals, 907,216 staffed beds, and more than 35.6 million hospital admissions in FY2024. The expanding hospital infrastructure and high patient volumes are expected to sustain demand for pressure ulcer prevention, monitoring, and treatment products across U.S. acute care settings.

The ambulatory surgery center segment of the pressure ulcer treatment market is expected to grow at the fastest rate during the forecast period. Growth is driven by the continued expansion of outpatient surgical infrastructure and the shift of procedures toward ambulatory settings. According to MedPAC, the number of Medicare-certified ASCs increased from 6,015 in 2021 to 6,436 in 2024, reflecting continued expansion of the U.S. ASC network. This expansion can support greater adoption of convenient wound-management solutions, including advanced dressings, pressure-redistribution products, wound cleansing products, and portable treatment systems.

To learn more about this report, Download Free Sample Report

Key U.S. Pressure Ulcer Treatment Company Insights

Some of the key companies in the U.S. pressure ulcer treatment market include SYST'AM, Ulcer Solutions, LLC., Stryker, Baxter (Hillrom), Arjo, LINET, Invacare Corporation, 3M, Smith+Nephew, Mölnlycke AB, Savaria, and Joerns Healthcare. Organizations are focusing on increasing customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as product launch, and partnerships with other major companies.

Key U.S. Pressure Ulcer Treatment Companies

• SYST'AM

• Ulcer Solutions, LLC.

• Stryker 

• Baxter (Hillrom)

• Arjo

• LINET

• Invacare Corporation

• 3M

• Smith+Nephew

• Mölnlycke AB

• Savaria

• Joerns Healthcare

• B. Braun SE

• Medline

• Convatec

• BioLab Holdings, Inc.

Recent Developments

• In August 2026, BioLab Holdings published a peer-reviewed real-world evidence study evaluating Membrane Wrap for complex pressure ulcers. The study found that 63.7% of patients receiving Membrane Wrap plus standard care were healing or healed, compared with 48.4% receiving standard care alone.

"Clinical studies are essential to understanding how advanced wound care technologies perform in real-world settings and to demonstrating efficacy across diverse patient populations," said Marshall Medley, DO, chief medical officer of BioLab Holdings and co-author of the study. "The more evidence we can generate, the better equipped providers are to evaluate treatment options."

• In June 2026, Smith+Nephew launched the next-generation LEAF Patient Monitoring System in the U.S., a data-driven platform designed to prevent hospital-acquired pressure injuries. The system provided real-time mobility monitoring, turn-status updates, EMR integration, and reporting to improve protocol adherence and patient care.

• In June 2026, Dimora Medical launched MegaSorb, a silicone foam dressing technology designed to provide high absorption efficiency, effective exudate management, and improved patient comfort.

U.S. Pressure Ulcer Treatment Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. pressure ulcer treatment market report based on product, clinical severity, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Wound Care Dressings

    • Moist

      • Foam Dressings

      • Hydrocolloid Dressings

      • Film Dressings

      • Alginate Dressings

      • Hydrogel Dressings

      • Collagen Dressings

      • Other Advanced Dressing

    • Antimicrobials

      • Silver

      • Non-silver

  • Active & Bio-Therapies

    • Active Biomaterials

    • Bioengineered Skin Substitutes

    • Growth Factors

  • Wound Care Devices & Systems

    • Negative Pressure Wound Therapy (NPWT)

    • Pressure Redistribution & Support Surfaces

    • Hyperbaric Oxygen Equipment

    • Electrical Stimulation Devices

  • Topical & Pharmacological Agents

    • Debriding Agents

    • Topical Antimicrobials & Antiseptics

  • Other Treatment Products

    • Offloading & Positioning Devices

    • Wound Cleansing & Irrigation Products

• Clinical Severity Outlook (Revenue, USD Million, 2021 - 2033)

  • Stage I

  • Stage II

  • Stage III

  • Stage IV

  • Deep Tissue Injury (DTI)

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Acute Care Hospital

  • Long-term Acute Care Hospital

  • Burn Center

  • Ambulatory Surgery Center

  • Hospital Outpatient Department Wound Care Clinic

  • Inpatient Rehabilitation Facility

  • Skilled Nursing Facility

  • Long-term Care (living setting)

  • Physician Office

  • Home Healthcare

Research Methodology

The U.S. pressure ulcer treatment market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each U.S. pressure ulcer treatment segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations